Changes to our trading names and address – MSD and Organon & Co. read more

Changes to our trading names and address

Please note that in 2021, MSD will be spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company known as Organon & Co.

Due to legal entity separation in advance of this spin off, we now have two UK registered businesses, MSD and Organon. Organon & Co. is a wholly owned subsidiary of Merck & Co., Inc. of Kenilworth, New Jersey, USA.

As a result of the future spin-off of Organon, as well as our head offices moving to London in early 2021, you will begin to see some changes to references to our products, contact details, materials and statements over the coming months.



Clinical Development

People count on us to make medicines that have well documented safety and effectiveness profiles and offer value. Clinical trials (also known as clinical studies) are a critical step in this process.

At any one time, we conduct approximately

 
 

These volunteers are playing a vital role in the rigorous and systematic testing process medicine must undergo before receiving approval. This process is designed to evaluate whether a new product should be approved for use in the broader population.

Our clinical trials are designed, conducted and monitored in adherence to the guidelines of The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

MSD clinical trials adhere to the same standards whether they take place in the UK or elsewhere around the world.

 
Code of Practice
Access to Data
Study Protocols

The ABPI Code of Practice requires that companies in the UK register current and future trials within 21 days of enrolling the first patient, and results must be published within one year of marketing authorisation or one year from completion for marketed products. We are pleased to be meeting these requirements.

Upon request, we also evaluate requests for access to clinical trial data from external researchers. Each request is evaluated based on criteria that balance the need to advance science with the need to protect intellectual property and confidential information (and in compliance with applicable privacy and data-protection laws, rules and regulations).

We provide clinical study protocols to biomedical journals when submitting a manuscript on a clinical trial, allowing journal editors and peer reviewers to use this protocol in their evaluation of the manuscript for publication (and, key sections of protocol may be published upon acceptance).

 

Phase I

Researchers test an experimental drug or treatment in a small group of healthy people (20–80) for the first time to evaluate its safety, determine an appropriate dosage, trace what happens to the compound in the body, and begin to identify side effects.

 

Phase II

The drug or treatment being studied is given to a larger group of people with the disease (100–300) to obtain preliminary evidence of an effect and to further evaluate its safety. If there is evidence of an effect and the risks are considered acceptable, the drug may move to the next stage.

 

Phase III

This phase of trial tests a drug candidate in a larger number of people with the disease (1,000–3,000) further testing its effectiveness and monitoring for side effects. In some cases this will be compared to a treatment standard, if one is already available.

 

Phase IV

After a drug or treatment has been approved by the appropriate government and regulatory agencies and is being marketed, we may study its safety and effectiveness over a longer period of time and in a larger number of people. We may also continue to study some of our marketed products for new indications. Thousands of people usually participate in Phase IV trials.

Job code: GB-NON-04173Date of preparation: April 2021